ReckMRodríguez-AbreuDRobinsonAG, et al.
Updated analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based chemotherapy for advanced non–Small-Cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol2019;
37: 537–546.
2.
RobertCLongGVBradyB, et al.
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med4: 311–319.
3.
SwainSMBaselgaJKimSB, et al.
Docetaxel in HER2-Positive metastatic breast cancer. N Engl J Med2015;
372: 724–734.
4.
FinnRSMartinMRugoHS, et al.
Palbociclib and letrozole in advanced breast. N Engl J Med2016;
375: 1925–1936.
5.
HortobagyiGNStemmerSMBurrisHA, et al.
Ribociclib as First-Line therapy for HR-Positiveadvanced breast cancer. N Engl J Med18: 1738–1748.
6.
ReckMRodríguez-AbreuDRobinsonAG, et al.
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med2016;
375: 1823–1833.
7.
ScagliottiGVParikhPPawelJ, et al.
Von. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. JCO2008;
26: 3543–3551.
